Loop Dx

Loop Dx, a Spain-based startup founded in 2018, is revolutionizing sepsis diagnostics with their innovative cell-mediated immune response technology. Their slogan "Cell-mediated immune response diagnostics to early predict sepsis" encapsulates their mission to provide early detection of sepsis through in vitro cellular immunoassays. Loop Dx's patented method and kit boasts a sensitivity 3 times greater than the industry leader, PCT, and their diagnostic process is 10 times faster than traditional pathogen identification.

The latest milestone for Loop Dx was the $30.00K Seed Round investment led by Health Wildcatters on 15 September 2020. This funding, combined with recent EU funding, provides a strong financial foundation for the company's plans to commercially launch disposable assays in 2024. As a disruptive player in the healthcare industry, Loop Dx holds promise for both investors and the healthcare sector, potentially redefining sepsis diagnostics and treatment. With a compelling value proposition and strong financial backing, Loop Dx is poised to make a significant impact in the fight against sepsis.